Advertisement
Review Article| Volume 50, ISSUE 1, P1-15, March 2023

Principles of Obstetric Pharmacology

Maternal Physiologic and Hepatic Metabolism Changes

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Obstetrics and Gynecology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Philipson A.
        Pharmacokinetics of ampicillin during pregnancy.
        J Infect Dis. 1977; 136: 370-376
        • Lund C.J.
        • Donovan J.C.
        Blood volume during pregnancy. Significance of plasma and red cell volumes.
        Am J Obstet Gynecol. 1967; 98: 394-403
        • Hytten F.
        Blood volume changes in normal pregnancy.
        Clin Haematol. 1985; 14: 601-612
        • Ouzounian J.G.
        • Elkayam U.
        Physiologic changes during normal pregnancy and delivery.
        Cardiol Clin. 2012; 30: 317-329
        • Petersen V.P.
        Body composition and fluid compartments in normal, obese and underweight human subjects.
        Acta Med Scand. 1957; 158: 103-111
        • Frederiksen M.C.
        • Ruo T.I.
        • Chow M.J.
        • et al.
        Theophylline pharmacokinetics in pregnancy.
        Clin Pharmacol Ther. 1986; 40: 321-328
        • Casele H.L.
        • Laifer S.A.
        • Woelkers D.A.
        • et al.
        Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy.
        Am J Obstet Gynecol. 1999; 181: 1113-1117
        • Mendenhall H.W.
        Serum protein concentrations in pregnancy. I. concentrations in maternal serum.
        Am J Obstet Gynecol. 1970; 106: 388-399
        • Bardy A.H.
        • Hiilesmaa V.K.
        • Teramo K.
        • et al.
        Protein binding of antiepileptic drugs during pregnancy, labor, and puerperium.
        Ther Drug Monit. 1990; 12: 40-46
        • Lees M.M.
        • Taylor S.H.
        • Scott D.B.
        • et al.
        A study of cardiac output at rest throughout pregnancy.
        J Obstet Gynaecol Br Commonw. 1967; 74: 319-328
        • Robson S.C.
        • Hunter S.
        • Boys R.J.
        • et al.
        Serial study of factors influencing changes in cardiac output during human pregnancy.
        Am J Physiol. 1989; 256: H1060-H1065
        • Capeless E.L.
        • Clapp J.F.
        When do cardiovascular parameters return to their preconception values?.
        Am J Obstet Gynecol. 1991; 165: 883-886
        • Metcalfe J.
        • Romney S.L.
        • Ramsey L.H.
        • et al.
        Estimation of uterine blood flow in normal human pregnancy at term.
        J Clin Invest. 1955; 34: 1632-1638
        • Ginsburg J.
        • Duncan S.L.
        Peripheral blood flow in normal pregnancy.
        Cardiovasc Res. 1967; 1: 132-137
        • Thoresen M.
        • Wesche J.
        Doppler measurements of changes in human mammary and uterine blood flow during pregnancy and lactation.
        Acta Obstet Gynecol Scand. 1988; 67: 741-745
        • Nakai A.
        • Sekiya I.
        • Oya A.
        • et al.
        Assessment of the hepatic arterial and portal venous blood flows during pregnancy with Doppler ultrasonography.
        Arch Gynecol Obstet. 2002; 266: 25-29
        • Odutayo A.
        • Hladunewich M.
        Obstetric nephrology: renal hemodynamic and metabolic physiology in normal pregnancy.
        Clin J Am Soc Nephrol. 2012; 7: 2073-2080
        • Andrew M.A.
        • Easterling T.R.
        • Carr D.B.
        • et al.
        Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies.
        Clin Pharmacol Ther. 2007; 81: 547-556
        • Eyal S.
        • Easterling T.R.
        • Carr D.
        • et al.
        Pharmacokinetics of metformin during pregnancy.
        Drug Metab Dispos. 2010; 38: 833-840
        • Hebert M.F.
        • Easterling T.R.
        • Kirby B.
        • et al.
        Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study.
        Clin Pharmacol Ther. 2008; 84: 248-253
        • Lin J.H.
        • Chiba M.
        • Baillie T.A.
        Is the role of the small intestine in first-pass metabolism overemphasized?.
        Pharmacol Rev. 1999; 51: 135-158
        • Zhao M.
        • Ma J.
        • Li M.
        • et al.
        Cytochrome P450 enzymes and drug metabolism in humans.
        Int J Mol Sci. 2021; 22: 12808
        • Sachar M.
        • Kelly E.J.
        • Unadkat J.D.
        Mechanisms of CYP3A induction during pregnancy: studies in HepaRG cells.
        AAPS J. 2019; 21: 45
        • Tracy T.S.
        • Venkataramanan R.
        • Glover D.D.
        • et al.
        Human development network of maternal-fetal-medicine U. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy.
        Am J Obstet Gynecol. 2005; 192: 633-639
        • Haas D.M.
        • Quinney S.K.
        • Clay J.M.
        • et al.
        Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic.
        Am J Perinatol. 2013; 30: 275-281
        • Ohkita C.
        • Goto M.
        Increased 6-hydroxycortisol excretion in pregnant women: implication of drug-metabolizing enzyme induction.
        DICP. 1990; 24: 814-816
        • Della Torre M.
        • Hibbard J.U.
        • Jeong H.
        • et al.
        Betamethasone in pregnancy: influence of maternal body weight and multiple gestation on pharmacokinetics.
        Am J Obstet Gynecol. 2010; 203: 254 e251-212
        • Stek A.
        • Best B.M.
        • Wang J.
        • et al.
        Pharmacokinetics of once versus twice daily darunavir in pregnant HIV-infected women.
        J Acquir Immune Defic Syndr. 2015; 70: 33-41
        • Unadkat J.D.
        • Wara D.W.
        • Hughes M.D.
        • et al.
        Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.
        Antimicrob Agents Chemother. 2007; 51: 783-786
        • Mirochnick M.
        • Best B.M.
        • Stek A.M.
        • et al.
        Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
        J Acquir Immune Defic Syndr. 2011; 56: 412-419
        • Stek A.M.
        • Mirochnick M.
        • Capparelli E.
        • et al.
        Reduced lopinavir exposure during pregnancy.
        AIDS. 2006; 20: 1931-1939
        • Mutagonda R.F.
        • Minzi O.M.S.
        • Massawe S.N.
        • et al.
        Pregnancy and CYP3A5 genotype affect day 7 plasma lumefantrine concentrations.
        Drug Metab Dispos. 2019; 47: 1415-1424
        • Westin A.A.
        • Brekke M.
        • Molden E.
        • et al.
        Treatment with antipsychotics in pregnancy: changes in drug disposition.
        Clin Pharmacol Ther. 2018; 103: 477-484
        • Prevost R.R.
        • Akl S.A.
        • Whybrew W.D.
        • et al.
        Oral nifedipine pharmacokinetics in pregnancy-induced hypertension.
        Pharmacotherapy. 1992; 12: 174-177
        • Xie H.G.
        • Wood A.J.
        • Kim R.B.
        • et al.
        Genetic variability in CYP3A5 and its possible consequences.
        Pharmacogenomics. 2004; 5: 243-272
        • Buchanan M.L.
        • Easterling T.R.
        • Carr D.B.
        • et al.
        Clonidine pharmacokinetics in pregnancy.
        Drug Metab Dispos. 2009; 37: 702-705
        • Hogstedt S.
        • Lindberg B.
        • Peng D.R.
        • et al.
        Pregnancy-induced increase in metoprolol metabolism.
        Clin Pharmacol Ther. 1985; 37: 688-692
        • Ververs F.F.
        • Voorbij H.A.
        • Zwarts P.
        • et al.
        Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy.
        Clin Pharmacokinet. 2009; 48: 677-683
        • Wadelius M.
        • Darj E.
        • Frenne G.
        • et al.
        Induction of CYP2D6 in pregnancy.
        Clin Pharmacol Ther. 1997; 62: 400-407
        • Ryu R.J.
        • Eyal S.
        • Easterling T.R.
        • et al.
        Pharmacokinetics of metoprolol during pregnancy and lactation.
        J Clin Pharmacol. 2016; 56: 581-589
        • Kwon Y.J.
        • Shin S.
        • Chun Y.J.
        Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes.
        Arch Pharm Res. 2021; 44: 63-83
        • Xie C.
        • Pogribna M.
        • Word B.
        • et al.
        In vitro analysis of factors influencing CYP1A2 expression as potential determinants of interindividual variation.
        Pharmacol Res Perspect. 2017; 5: e00299
        • Koh K.H.
        • Jurkovic S.
        • Yang K.
        • et al.
        Estradiol induces cytochrome P450 2B6 expression at high concentrations: implication in estrogen-mediated gene regulation in pregnancy.
        Biochem Pharmacol. 2012; 84: 93-103
        • Walsky R.L.
        • Astuccio A.V.
        • Obach R.S.
        Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.
        J Clin Pharmacol. 2006; 46: 1426-1438
        • Cressey T.R.
        • Stek A.
        • Capparelli E.
        • et al.
        Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.
        J Acquir Immune Defic Syndr. 2012; 59: 245-252
        • Bogen D.L.
        • Perel J.M.
        • Helsel J.C.
        • et al.
        Pharmacologic evidence to support clinical decision making for peripartum methadone treatment.
        Psychopharmacology (Berl). 2013; 225: 441-451
        • Choi S.Y.
        • Koh K.H.
        • Jeong H.
        Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone.
        Drug Metab Dispos. 2013; 41: 263-269
        • Hebert M.F.
        • Ma X.
        • Naraharisetti S.B.
        • et al.
        Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice.
        Clin Pharmacol Ther. 2009; 85: 607-614
        • Rytting E.
        • Nanovskaya T.N.
        • Wang X.
        • et al.
        Pharmacokinetics of indomethacin in pregnancy.
        Clin Pharmacokinet. 2014; 53: 545-551
        • Tomson T.
        • Lindbom U.
        • Ekqvist B.
        • et al.
        Disposition of carbamazepine and phenytoin in pregnancy.
        Epilepsia. 1994; 35: 131-135
        • Yerby M.S.
        • Friel P.N.
        • McCormick K.
        • et al.
        Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding.
        Epilepsy Res. 1990; 5: 223-228
        • Tornio A.
        • Backman J.T.
        Cytochrome P450 in Pharmacogenetics: An Update.
        Adv Pharmacol. 2018; 83: 3-32
        • McGready R.
        • Stepniewska K.
        • Seaton E.
        • et al.
        Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil.
        Eur J Clin Pharmacol. 2003; 59: 553-557
        • Mwinyi J.
        • Cavaco I.
        • Pedersen R.S.
        • et al.
        Regulation of CYP2C19 expression by estrogen receptor alpha: implications for estrogen-dependent inhibition of drug metabolism.
        Mol Pharmacol. 2010; 78: 886-894
        • Jeong H.
        • Choi S.
        • Song J.W.
        • et al.
        Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination.
        Xenobiotica. 2008; 38: 62-75
        • Fischer J.H.
        • Sarto G.E.
        • Hardman J.
        • et al.
        Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy.
        Clin Pharmacokinet. 2014; 53: 373-383
        • Rogers R.C.
        • Sibai B.M.
        • Whybrew W.D.
        Labetalol pharmacokinetics in pregnancy-induced hypertension.
        Am J Obstet Gynecol. 1990; 162: 362-366
        • Tomson T.
        • Ohman I.
        • Vitols S.
        Lamotrigine in pregnancy and lactation: a case report.
        Epilepsia. 1997; 38: 1039-1041
        • Reimers A.
        • Helde G.
        • Brodtkorb E.
        Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations.
        Epilepsia. 2005; 46: 1414-1417
        • Chen H.
        • Yang K.
        • Choi S.
        • et al.
        Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy.
        Drug Metab Dispos. 2009; 37: 1841-1847
        • Fotopoulou C.
        • Kretz R.
        • Bauer S.
        • et al.
        Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period.
        Epilepsy Res. 2009; 85: 60-64
        • Karanam A.
        • Pennell P.B.
        • French J.A.
        • et al.
        Lamotrigine clearance increases by 5 weeks gestational age: Relationship to estradiol concentrations and gestational age.
        Ann Neurol. 2018; 84: 556-563
        • Ohman I.
        • Beck O.
        • Vitols S.
        • et al.
        Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy.
        Epilepsia. 2008; 49: 1075-1080
        • Polepally A.R.
        • Pennell P.B.
        • Brundage R.C.
        • et al.
        Model-based lamotrigine clearance changes during pregnancy: clinical implication.
        Ann Clin Transl Neurol. 2014; 1: 99-106
        • O'Sullivan M.J.
        • Boyer P.J.
        • Scott G.B.
        • et al.
        The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group.
        Am J Obstet Gynecol. 1993; 168: 1510-1516
        • Nylen H.
        • Sergel S.
        • Forsberg L.
        • et al.
        Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4beta-hydroxycholesterol.
        Eur J Clin Pharmacol. 2011; 67: 715-722
        • Kim A.H.
        • Kim B.
        • Rhee S.J.
        • et al.
        Assessment of induced CYP3A activity in pregnant women using 4beta-hydroxycholesterol: Cholesterol ratio as an appropriate metabolic marker.
        Drug Metab Pharmacokinet. 2018; 33: 173-178
        • Johnson E.L.
        • Stowe Z.N.
        • Ritchie J.C.
        • et al.
        Carbamazepine clearance and seizure stability during pregnancy.
        Epilepsy Behav. 2014; 33: 49-53
        • Thomas A.G.
        • Burrows L.
        • Knight R.
        • et al.
        The effect of pregnancy on cyclosporine levels in renal allograft patients.
        Obstet Gynecol. 1997; 90: 916-919
        • Zheng S.
        • Easterling T.R.
        • Umans J.G.
        • et al.
        Pharmacokinetics of tacrolimus during pregnancy.
        Ther Drug Monit. 2012; 34: 660-670